Research and Markets has announced the addition of the "Immunotherapy Drugs Market by Type of Drugs, Therapy Area - Global Forecast to 2021" report to their offering.

The global immunotherapy drugs market is projected to reach USD 201.52 billion by 2021 from USD 108.41 billion in 2016, growing at a CAGR of 13.5% during the forecast period of 2016 to 2021.

In this report, the immunotherapy drugs market is segmented on the basis of type of drugs, therapy area, end user, and region. Increasing adoption of targeted therapies with fewer side effects, quicker drug approval processes, and high prevalence rate of lifestyle diseases are major growth drivers of this market. On the other hand, the high cost of immunotherapy treatment, and high attrition rate in the product development cycle are the major factors hindering the growth of the immunotherapy drugs market. However, rising opportunities in the emerging markets, and immunotherapy as an alternative to chemotherapy for first line treatment are the factors supporting the growth of immunotherapy drugs market.

North America is expected to account for largest share in the immunotherapy drugs market, by region in 2016. Asia-Pacific is expected to be the fastest-growing regional segment in the immunotherapy drugs market. The high growth of this segment can primarily be attributed to the low cost of manufacturing and acceptable regulatory scenario in this region.

Companies Mentioned:

  • Abbvie
  • Amgen Inc.
  • Astrazeneca
  • Bristol-Myers Squibb
  • ELI Lilly and Company
  • F. Hoffmann-La Roche AG
  • Glaxosmithkline PLC
  • Johnson & Johnson (A Parent Company of Janssen Biotech, Inc.)
  • Merck & Co., Inc.
  • Novartis International AG

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Industry Insights

7 Immunotherapy Drugs Market, By Type of Drug

8 Immunotherapy Drugs Market, By Therapy Area

9 Immunotherapy Drugs Market, By End User

10 Immunotherapy Drugs Market, By Region

11 Competitive Landscape

12 Company Profiles

13 Appendix

For more information about this report visit http://www.researchandmarkets.com/research/2nz244/immunotherapy